GCG and metabolic dysfunction-associated steatohepatitis: Compared to the control group, GLP-1 agonists were associated with a statistically significant increase in the resolution of MASH without worsening fibrosis (RR 3.03, <i>p</i> < 0.0001) and at least one stage of liver fibrosis without the worsening of MASH compared to the control group (RR: 1.45, <i>p</i> < 0.00001).